1. Eagle KA, Berger PB, Calkins H, et al: ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Anesth Analg94:1052-1064, 2002.
2.
2. Shoemaker WC: Cardiorespiratory patterns of surviving and non-surviving postoperative surgical patients. Surg Gynecol Obstet134:801-814, 1972.
3.
3. Shoemaker WC, Appel PL, Bland R: Use of physiological monitoring to predict outcome and to assist in clinical decisions in critically ill postoperative patients. Am J Surg1:43-50, 1983.
4.
4. Shoemaker WC, Appel PL, Krarn HB, et al: Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest94:1176-1186, 1983.
5.
5. Boyd O, Bennett ED: Enhancement of perioperative tissue perfusion as a therapeutic strategy for major surgery. New Horiz4:453-465, 1996.
6.
6. Boyd O, Grounds RM, Bennett ED: A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA270:2699-2707, 1993.
7.
7. Guest JF, Boyd O, Hart WM, Grounds RM, et al: A cost analysis of a treatment policy of a deliberate perioperative increase in oxygen delivery in high-risk surgical patients. Intensive Care Med23:85-90, 1997.
8.
8. Zaugg M, Tagliente T, Lucchinetti E, et al: Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery. Anesthesiology91:1674-1686, 1999.
9.
9. Raby KE, Brull SJ, Timimi F, et al: The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg88:477-482, 1999.
10.
10. Poldermans D, Boersma E, Bax JJ, et al: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med341:1789-1794, 1999.
12. Metro M, Nodari S, D'Aloia A, et al: A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J139:511-521, 2000.
13.
13. Braunwald E: Expanding indications for beta-blockers in heart failure. N Engl J Med344:1711-1712, 2001.
14.
14. Metro M, Giubbini R, Nodari S, et al: Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the longterm effects of metoprolol versus carvedilol. Circulation102:546-551, 2001.
15.
15. Packer M, Coats AJ, Fowler MB, et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med344:1651-1658, 2001
16.
16. Reiz S, Balfors E, Swensen MB, et al: Isofluranea powerful coronary vasodilator in patients with coronary artery disease. Anesthesiology59:91-97, 1983.
17.
17. Warltier DC, Al-Wathiqui MH, Kampine JR, Schmeling WT: Recovery of contractile function of “stunned” myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiology69:552-565, 1988.
18.
18. Kersten JR, Schmeling TJ, Hettrick DA, et al: Mechanism of myocardial protection by isoflurane: Role of adenosine triphosphate-regulated potassium (KATP) channels. Anesthesiology85:794-807, 1996.
19.
19. Karsten JR, Schmeling TJ, Pagel PS, Gross GJ, et al: Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: Reduction of myocardial infarct size with an acute memory phase. Anesthesiology87:361-370, 1997.
20.
20. Canon BA, Gamperl AK, Slocum RE, Hickey RF: Anestheticinduced preconditioning: Previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology87:1182-1190, 1997.
21.
21. Belhomme D, Peynet J, Louzy M, et al: Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation100:II-340-II-344, 1999.
22.
22. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation74:1124-1136, 1986.
23.
23. Laskey WK: Beneficial impact of preconditioning during PTCA on creating kinase release. Circulation99:2085-2089, 1999.
24.
24. Kersten JR, Schmeling TJ, Hettrick DA, et al: Mechanism of myocardial protection by isoflurane: Role of adenosine triphosphate-regulated potassium (KATP) channels. Anesthesiology85:794-807, 1996.
25.
25. Roscoe AK, Christensen JD, Lynch C: Isoflurane, but not halothane, induces protection of human myocardium via adenosine Al receptors and adenosine triphosphate-sensitive potassium channels. Anesthesiology92:1692-1670, 2000.
26.
26. Piriou V, Chiari R, Knezynski S, et al: Prevention of isoflurane-induced preconditioning by 5-hydroxydecanoate and gadolinium. Anesthesiology93:756-764, 2000.
27.
27. Toller WG, Kersten JR, Pagel PS, Hettrick DA, et al: Sevoflurane reduces myocardial infarct size and decreases the time threshold for ischemic preconditioning in dogs. Anesthesiology91:1437-1446, 1999.
28.
28. Toller WG, Gross ER, Kersten JR, et al: Sarcolemmal and mitochondrial adenosine triphosphate-dependent potassium channels: Mechanism of desflurane-induced cardioprotection. Anesthesiology92:1731-1739, 2000.
29.
29. Zaugg M, Lucchinetti E, Spahn D, Pasch T, et al: Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitoKATP channels via rnultiple signaling pathways. Anesthesiology97:4-14, 2002.
30.
30. Zaugg M, Lucchinetti E, Spahn D, et al: Differential effects of anesthetics on mitochondrial KATP channel activity and cardiomyocyte protection. Anesthesiology97:15-23, 2002.
31.
31. Kwok W, Martinelli A, Fujimoto K, et al: Differential modulation of the cardiac ATP-sensitive potassium channel by volatile anesthetics. Anesthesiology97:50-56, 2002.
32.
32. Fujimoto K, Bosnjak Z, Kwok W: Isoflurane-induced facilitation of the cardiac sarcolemmal KATP channel. Anesthesiology97:57-65, 2002.
33.
33. Hanouz J, Yvon A, Massetti M, et al: Mechanisms of desflurane-induced preconditioning in isolated human right atrium in vitro. Anesthesiology97:33-34, 2002.
34.
34. De Hert S, ten Broecke R, Mertens E, et al: Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology97:42-49, 2002.
35.
35. Haroun-Bizri S, Khoury SS, Chehab IR, Kassas CM, et al: Does isoflurane optimize myocardial protection during cardiopulmonary bypass?J Cardiothorac Vasc Anesth15:418-421, 2001.
36.
36. Penta de Peppo A, Polisca R, Tomai F, et al: Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. Ann Thorac Surg68:112-118, 1999.
37.
37. Lowenstein E, Hallowell R, Levlne FH, et al: Cardiovascular response to large doses of intravenous morphine in man. N Engl J Med281:1389-1393, 1969.
39. Lowenstein E, Philbin DM: Narcotic ‘anesthesia’ in the Eighties. Anesthesiology55:195-197, 1981.
40.
40. Schultz JE, Gross GJ: Opioids and cardioprotection. Pharmacol Ther89:123-137, 1981.
41.
41. Genade S, Moolman JA, Lochner A: Opioid receptor stimulation acts as mediator of protection in ischaemic preconditioning. Cardiovasc J S Afr12:8-16, 2001.
42.
42. Sigg DC, Coles JA, Gallagher WJ, Oeltgen PR, et al: Opioid preconditioning: Myocardial function and energy metabolism. Ann Thorac Surg72:1576-1582, 2001.
43.
43. Schultz JE, Hsu AK, Gross GJ: Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heartCirc Res78:1100-1104, 1996.
44.
44. Cohen MV, Yang XM, Liu GS, Heusch G, et al: Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. Circ Res89:273-278, 2001.
45.
45. Fryer RM, Hsu AK, Eells JT, Nagase H, et al: Opioid-induced second window of cardioprotection: Potential role of mitochondrial KATE channels. Circ Res84:846-851, 1999.
46.
46. Liang BT, Gross GJ: Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Cfc Res25:84:1396-1400, 1999.
47.
47. Ocana M, Del Pozo E, Barrios M, Robels LI, et al: An ATPdependent potassium channel blocker antagonizes morphine analgesia. Eur J Pharrnacol186:377-378, 1990.
48.
48. Raffa RB, Martinez RP: The “glibenclamide-shift” of centrally-acting antinociceptive agents in mice. Brain Res67:277-282, 1995.
49.
49. Welch SP, Dunlow LD: Antinociception activity of intrathecally administered potassium channel openers and opioid agonists: A common mechanism of action. J Pharmacol Exp Ther267:390-399, 1993.
51. Takasaki Y, Wolff RA, Chien GL, van Winkle DM: Met5enkephalin protects isolated adult rabbit cardiomyocytes via delta-opioid receptors. Am Physiol277:H2442-H2450, 1999.
52.
52. Sigg DC, Coles JA, Oeltgen PR, Laizzo PA: Role of deltaopioid receptor agonists on infarct size reduction in swine. Am J Physiol Heart Circ Physiol282:H1953-H1960, 2002.
53.
53. Bolling SF, Badhwar V, Schwartz CF, et al: Opioids confer myocardial tolerance toischemia: Interaction of delta opioid agonists and antagonists. J Thorac Cardiovasc Surg122:476-481, 2001.
54.
54. Kato R, Ross S, Foex P: Fentanyl protects the heart against ischaemic injury via opioid receptors, adenosine Al receptors and KATP channel linked mechanisms in rats. Br J Anaesth84:204-214, 2000.
55.
55. Downey JM, Cohen MV: Signal transduction in ischemic preconditioning, in Sidman S, Beyar R (eds): Analytical and Quantitative Cardiology. New York: Plenum Press, 1997, pp 30-55.
56.
56. Cahill CM, White TD, Sawynok J: Synergy between g/6opioid receptors mediate adenosine release from spinal cord synaptosomes. Eur J Pharmacol298:45-49, 1996.
57.
57. Mantle JA, Rogers WJ, Smith LR, et al: Clinical effects of glucose-insulin-potassium on left ventricular function in acute myocardial infarction: Results from a randomized clinical trial. Am Heart J102:313-324, 1981.
58.
58. Rackley CE, Rogers RO, Rogers WJ, et al: Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J102:1038-1049, 1981.
59.
59. Neely JR, Grotyohann LV: Role of glycolytic products in damage to ischemic myocardium: Dissociation of adenosine triphosphate levels and recovery of perfused ischemic hearts. Circ Res55:816-816, 1984.
60.
60. Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. Circulation96:1152-1156, 1997.
61.
61. Malmburg K: Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br Med J314:1512-151, 1997.
62.
62. Diaz R, Paolasso EA, Piegas LS, et al: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation98:2227-2234, 1998.
63.
63. Satler LF, Green CE, Kent KM, et al: Metabolic support during coronary reperfusion. Am Heart J114:54-58, 1987.
64.
64. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet343:155-158, 1994.
65.
65. Rao V, Meranta F, Weisen RD, et al: Insulin stimulates pyruvate dehydrogenase and protects human ventricular myocytes from simulated ischemia. J Thorac Cardiovasc Surg116:485-494, 1998.
